Khera Nandita, Martin Patricia, Edsall Kristen, Bonagura Anthony, Burns Linda J, Juckett Mark, King Olivia, LeMaistre C Frederick, Majhail Navneet S
Mayo Clinic Arizona, Phoenix, AZ.
Anthem Inc., Indianapolis, IN.
Blood Adv. 2017 Aug 22;1(19):1617-1627. doi: 10.1182/bloodadvances.2017008789.
Hematopoietic cell transplantation (HCT) is an expensive, resource-intensive, and medically complicated modality for treatment of many hematologic disorders. A well-defined care coordination model through the continuum can help improve health care delivery for this high-cost, high-risk medical technology. In addition to the patients and their families, key stakeholders include not only the transplantation physicians and care teams (including subspecialists), but also hematologists/oncologists in private and academic-affiliated practices. Initial diagnosis and care, education regarding treatment options including HCT, timely referral to the transplantation center, and management of relapse and late medical or psychosocial complications after HCT are areas where the referring hematologists/oncologists play a significant role. Payers and advocacy and community organizations are additional stakeholders in this complex care continuum. In this article, we describe a care coordination framework for patients treated with HCT within the context of coordination issues in care delivery and stakeholders involved. We outline the challenges in implementing such a model and describe a simplified approach at the level of the individual practice or center. This article also highlights ongoing efforts from physicians, medical directors, payer representatives, and patient advocates to help raise awareness of and develop access to adequate tools and resources for the oncology community to deliver well-coordinated care to patients treated with HCT. Lastly, we set the stage for policy changes around appropriate reimbursement to cover all aspects of care coordination and generate successful buy-in from all stakeholders.
造血细胞移植(HCT)是一种用于治疗多种血液系统疾病的昂贵、资源密集且医学上复杂的治疗方式。贯穿整个连续过程的明确的护理协调模式有助于改善这种高成本、高风险医疗技术的医疗服务提供。除了患者及其家属外,关键利益相关者不仅包括移植医生和护理团队(包括专科医生),还包括私人诊所和学术附属机构的血液学家/肿瘤学家。初始诊断和护理、关于包括HCT在内的治疗选择的教育、及时转诊至移植中心以及HCT后复发和晚期医疗或心理社会并发症的管理,都是转诊血液学家/肿瘤学家发挥重要作用的领域。支付方以及倡导和社区组织是这个复杂护理连续过程中的其他利益相关者。在本文中,我们在护理提供中的协调问题以及相关利益者的背景下,描述了接受HCT治疗患者的护理协调框架。我们概述了实施这种模式的挑战,并描述了个体诊所或中心层面的简化方法。本文还强调了医生、医疗主任、支付方代表和患者倡导者正在做出的努力,以帮助提高认识并为肿瘤学界提供适当的工具和资源,以便为接受HCT治疗的患者提供协调良好的护理。最后,我们为围绕适当报销的政策变革奠定基础,以涵盖护理协调的各个方面,并获得所有利益相关者的成功认可。